Synairgen PLC’s (LON:SNG) chief executive Richard Marsden speaks to Proactive's Katie Pilbeam as the firm finds themselves 'right in the middle of a global emergency'.
Marsden talks about their 'role' and their 'exceptional progress' for the whole group over 2020 as it continued to develop its treatment for coronavirus (COVID-19) infections.
He hails the speed at which his team has been working, 'doing five years of work in two', with the Phase III trial of SNG001 already initiated and the results are expected in the second half of this year after the first patient was dosed in January.